ECM
TRML

ExodusPoint Capital Management’s Tourmaline Bio TRML Stock Holding History

ExodusPoint Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,650
Closed -$279K – 1965
2023
Q4 		$279K Buy
+10,650
New +$213K ﹤0.01% 1200

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

ExodusPoint Capital Management's TRML Position: Q1 2024 in Review

ExodusPoint Capital Management sold out of Tourmaline Bio (TRML) in Q1 2024, closing a stake of 10,650 shares — an estimated $279K sold.

ExodusPoint Capital Management first reported a position in TRML in Q4 2023 and held it in 1 quarter. The position peaked at $279K in Q4 2023. 96 funds tracked by Wall St. Rank hold TRML as of Q1 2024.

  • ExodusPoint Capital Management reported no remaining Tourmaline Bio position as of Q1 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 10,650 Tourmaline Bio shares in Q1 2024, an estimated $279K.
  • ExodusPoint Capital Management first reported a position in Tourmaline Bio in Q4 2023 and held it in 1 quarter.
  • ExodusPoint Capital Management's Tourmaline Bio position peaked at $279K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2024.

Based on ExodusPoint Capital Management's 13F filing for Q1 2024, filed 14 May 2024.